Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors

Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors

Regulatory News:

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect.

A Director of Theraclion since the General Meeting of June 18, 2026, after having served as an observer over recent months, Vincent Gardès succeeds Mr. Claude Lenoir, who had served as Interim Chairman of the Board of Directors since that date and who remains a Director of the Company.

This appointment comes at a pivotal moment for Theraclion, which has recently achieved several major milestones: MDR certification and growing commercial momentum in Europe, the first clinical implementation in China, the submission of the Sonovein® file to the FDA, the granting of a Category III CPT code in the United States, and a recent successful capital increase. The arrival of Vincent Gardès, an experienced executive with a proven track record in the international development of MedTech companies and a specialist in commercial strategy, significantly strengthens Theraclion’s governance.